Accueil>>Signaling Pathways>> PI3K/Akt/mTOR Signaling>> GSK-3>>3F8

3F8

Catalog No.GC14306

Le 3F8 est un inhibiteur puissant et sélectif de la GSK-3β qui pourrait être utile comme nouveau réactif et candidat thérapeutique potentiel pour les maladies liées À la GSK3.

Products are for research use only. Not for human use. We do not sell to patients.

3F8 Chemical Structure

Cas No.: 159109-11-2

Taille Prix Stock Qté
10mg
140,00 $US
En stock
50mg
536,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

IC50: 34 and 304 nM in the presence of 10 and 100 μM ATP, respectively.

3F8 is a potent and selective GSK-3β (Glycogen Synthase Kinase 3) inhibitor

GSK3 was identified as a serine/threonine protein kinase for the first time in the late 1970s and is highly conserved in all animals examined. GSK3 can regulate cell differentiation and apoptosis, and is an important component of the canonical Wnt pathway as well as the hedgehog pathway

In vitro: 3F8 specifically abolishes eye and forebrain formation in zebrafish embryos with the similar as a typical Wnt overexpression phenotype. Cell reporter assays, chemical informatics analysis and in vitro kinase experiments exhibited that 3F8 is a selective GSK3 inhibitor with more potent than SB216763 (a commonly used GSK3 inhibitor). Together, 3F8 and its derivatives could be useful as new agents and potential therapeutic candidates for GSK3 related diseases [1].

The interaction of 3F8 with its binding site were studied. To this end, first computational analysis conducted, and the results suggested that maleimide moiety of 3F8 might interact with the ATP binding site of GSK-3β, and the N-4 and C-5 positions were solvent-exposed, indicating the less key role of this region to the binding affinity. [2].

In vivo: The lowest ratio (CE/IC50 = 221) of 3F8 implied that 3F8 was more efficient in vivo, likely according to better absorption and/or stability [1]. By injection of a sub-lethal amount of morpholino antisense oligonucleotides, individual knockdown of gsk3a and gsk3b translations in zebrafish caused cardiac defect [1].

Clinical trial: Clinical study has been conducted.

References:
[1].  Zhong H, Zou H, Semenov MV, Moshinsky D, He X, Huang H, Li S, Quan J, Yang Z, Lin S. Characterization and development of novel small-molecules inhibiting GSK3 and activating Wnt signaling. Mol Biosyst. 2009 Nov;5(11):1356-60.
[2].  Zou H, Zhou L, Li Y, Cui Y, Zhong H, Pan Z, Yang Z, Quan J. Benzo[e]isoindole-1,3-diones as potential inhibitors of glycogen synthase kinase-3 (GSK-3). Synthesis, kinase inhibitory activity, zebrafish phenotype, and modeling of binding mode. J Med Chem. 2010 Feb 11;53(3):994-1003.

Avis

Review for 3F8

Average Rating: 5 ★★★★★ (Based on Reviews and 6 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 3F8

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.